Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. John's wort

This article was originally published in The Tan Sheet

Executive Summary

Thirty-nine of 472 SJW-related adverse event reports submitted to FDA through Dec. 11, 2000 indicated "possible" pharmacokinetic interactions with substrates of P450 CYP3A and/or p-glycoprotein (cyclosporin, levonorgestrel/ estradiol and sildenafil) as well as serotonin reuptake inhibitors, according to agency researchers. AERs show SJW may result in exaggerated hypertensive reactions when taken with SSRIs and "decrease expected effect" of the three drugs, but researchers stress "additional studies are needed to assess mechanistic issues and the full spectrum of clinical implications arising from these interactions." FDA and NIH issued warnings on concomitant use of SJW supplements and protease inhibitors in early 2000 (1"The Tan Sheet" Feb. 14, 2000, p. 19)
Advertisement

Related Content

Lutein Drove Recent Supplement Growth; Single Herbs Stayed Flat – Study
Lutein Drove Recent Supplement Growth; Single Herbs Stayed Flat – Study
Dietary Supplement Adverse Events “Mild” 71% Of Time, Lancet Study Finds
Dietary Supplement Adverse Events “Mild” 71% Of Time, Lancet Study Finds
St. John's Wort/HIV Protease Inhibitor Use Warnings Issued By FDA, NIH
St. John's Wort/HIV Protease Inhibitor Use Warnings Issued By FDA, NIH

Topics

Advertisement
UsernamePublicRestriction

Register

PS093189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel